Procarbazine has exhibited antitumor activity in a spectrum of transplanted animal tumors) ,4 and has been proved particularly effective against the intracerebral L1210 leukemia model. Pharmacokinetic studies indicate that it crosses the blood-brain barrier (BBB) either directly or in metabolite form, 4 a property that appears now to be one prerequisite for an agent's use in drug therapy of central nervous system tumors. 5 For more than 6 years, Procarbazine has been used with considerable success in Hodgkins disease either alone or in combination, and with varying degrees of success in the treatment of other solid tumors. 1,a,7,8 On the basis of these reports, we selected Procarbazine for a Phase 2 trial in 43 patients with malignant brain tumors.
Analysis of Cases

Patient Selection
Forty-three patients received one or more courses of Procarbazine during the period April, 1971, to September, 1972 . Patients in the following categories were accepted into the study: 1) those with primary tumors of the neuraxis who had undergone an operation (including biopsy), followed in most cases by radiotherapy, and who showed progressive clinical deterioration due to regrowth of residual tumor measurable by either brain scan or contrast radiographic studies; 2) patients with confirmed intracerebral metastatic tumors; and 3) patients with brain-stem or deep thalamic mass lesions that had not been confirmed surgically due to the critical location of the tumor, but whose tumors were indicated and confirmed by clinical examination, brain scan, electroencephalography (EEG), and radiographic studies.
Patients in these groups were included whether or not they had undergone a full or partial course of radiation therapy, provided that the therapy had been concluded at least 3 months prior to the initiation of Procarbazine therapy. (One patient who began treatment 6 weeks after completing radiotherapy was assigned to the non-evaluatable group). When the diagnosis had been established by partial resection or biopsy, the histological slides were reviewed for confirmation of tumor type.
We assumed that corticosteroids (for instance, dexamethasone) have no significant antitumor effect and that steroidrelated improvement in neurological signs and symptoms was attributable to a reduction in the cerebral edema associated with the neoplasm. Changes in steroid therapy were taken into consideration in the evaluation of changes in the patients' clinical condition, brain scans and other radiographic studies. Prior to treatment the individual steroid dose was tapered to the minimum amount required to maintain the patient in a reasonable neurological state.
When steroid therapy was initiated by us, the dose was increased at intervals of 48 to A. R. Vasantha Kumar, et al. 72 hours until a reasonable neurological state was reached. If patients were receiving steroids at the time of referral for chemotherapy, the steroid was discontinued when possible. If the patient proved to be steroiddependent, i.e., without steroid support the neurological state declined to an unacceptable level, dexamethasone was administered in the lowest maintenance dose required to achieve the desired result. Adjusting the maintenance dose of steroids ordinarily required 1 week or longer. Baseline studies were obtained after steroid requirements were established.
We also assumed that the standard anticonvulsant medications (such as diphenylhydantoin, phenobarbital, diazepam) received by the majority of our patients have no significant antitumor effect.
Patients were excluded from this study if: 1 ) death occurred before the date that the second course was to be started (60 days from beginning of treatment); 2) another form of therapy was considered necessary for the better care of the patient during this same 60-day period; and 3) autopsy findings did not show tumor recurrence. (Two brains showed radiation necrosis instead of tumor.)
Evaluation of Cases
The initial inpatient clinical evaluation included a general physical and neurological examination, urinalysis, complete blood count, platelet count, blood urea nitrogen, creatinine, glucose, serum glutamic oxaloacetic transaminase, lactate dehydrogenase, alkaline phosphatase, and bilirubin levels.
For each patient a brain scan (technetium 99M), EEG, and one or more radiographic contrast studies appropriate to the type and location of the tumor were obtained. Cytological examination for malignant ceils and customary studies were performed on cerebrospinal fluid (CSF) in some cases, such as cases of medulloblastoma and meningeal carcinomatosis. Psychological evaluation was obtained when pertinent.
When a patient was readmitted for retreatment, the same evaluation was carried out except that the radiographic studies were repeated only if changes in the brain scan failed to correlate with clinical changes or if reoperation was under consideration.
After the initiation of each course of treatment, patients were discharged to their home, a nursing home, or another hospital. During the course of the treatment, twice weekly complete blood and platelet counts and basic liver function studies were done on an outpatient basis; these were recorded on chemotherapy flow sheets and carefully monitored for toxicity.
Treatment
Procarbazine is supplied in 50 mg capsules for oral administration, and 150 mg/m2/day for a period of 30 days constituted the initial course of treatment. The recommended dose was reached in daily 50 mg increments to reduce nausea and vomiting. After a full 30-day course of Procarbazine patients stopped treatment for 30 days before the beginning of the next course. The dosage in subsequent courses was determined by the degree of myelosuppression. Nausea and vomiting often occurred during the first few days of each course, but all courses were completed with one exception, a child aged 3 89 years with a temporoparietal ependymoblastoma.
Barbiturates, antihistamines, narcotics, hypotensive agents, and phenothiazenes were either avoided or used with extreme caution. Because Procarbazine exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs and food with high tyramine content, such as cheese and bananas, were avoided.
End Point
A patient was considered to have completed the study when: 1 ) death occurred; 2) another form of therapy, such as operation, was considered essential for the well-being of the patient; 3) we could not re-evaluate and retreat according to the protocol; or 4) the condition of the patient, over a period of one or more courses of treatment, remained in a state where practical considerations demanded that treatment be discontinued.
At the present time we have no end point for patients who continue to respond, and A total of 43 patients harboring tumors of the central nervous system were treated. In Table 1 these tumors are classified by established or probable pathological diagnosis. Therapy undergone prior to entering the study is indicated in Table 2 .
Ten patients could not be evaluated because death occurred before completion of the first full course (60 days) ; the patient or relative responsible declined to continue treatment; or autopsy revealed no evidence of tumor.
Radiation necrosis caused the death of two patients. With greater interest in new therapeutic approaches to recurrent brain tumors, the problem of radionecrosis is certain to be a serious consideration in the differential diagnosis of a recurrent mass lesion. Patients who showed evidence of two or more of the following criteria were considered as unequivocal responders: improvement in neurological status; improvement in brain scan, i.e., decrease in the size of the barrier defect; or stability of neurological state after significant reduction or discontinuation of steroid therapy. Patients who fulfilled just one of the preceding three criteria were considered as probable responders.
Patients whose neurological status and/or brain scan was growing worse and needed either the same or higher doses of steroid therapy to maintain a stable neurological status were considered as failures. Patients who remained unchanged in their neurological status, with no change in their brain scan and steroid therapy, were also considered as failures. Patients who showed only EEG improvement were not considered as responders.
Of the 29 evaluatable patients, 12 patients (41%) showed remission of their neurological deterioration and were either stable or showed improvement that could not be accounted for by Decadron and/or other adjuvant therapy. Two patients (7%) were considered as probable responders.
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The duration of tumor regression ranged from 2 to 19 months with a median response of 7 months (Table 3 ).
The tumors of four patients who had received previous chemotherapy (3 CCNU and 1 BCNU) were unresponsive to Procarbazine.
Results
The following are two typical case reports of patients responsive to Procarbazine.
Case Reports Case 1. This 13-year-old boy, was admitted to the medical center in August, 1971, because of pain in the cervicothoracic region, difficulty in starting urination, weakness in both hand grips and an unsteady gait with a tendency to fall towards the right side. Six years earlier he had undergone subtotal resection of a medulloblastoma. Postoperatively he had received a course of radiation to the posterior fossa (3000 R). In 1969, he developed a recurrent cerebellar mass for which he received a second course of radiation (3500 R). He improved and did well until shortly before admission to our chemotherapy service. When examined he was an alert and welloriented boy with nystagmus in both vertical and horizontal gaze and ataxia of the right arm and leg. Intrinsic hand muscles were wasted with hypesthesia in the right C-8 distribution. Deep tendon reflexes were hyperactive in both legs with a left Babinski sign. Four-vessel angiography and a pneumoencephalogram revealed slight dilatation of the lateral ventricles and a recurrent mass involving the right cerebellar hemisphere. Pantopaque myelography showed a total block at T-11 with multiple filling defects from L-3 through L-5, consistent wtih seeding from a known medulloblastoma (Fig. 1) . The CSF had a protein content of 480 mg% and cytological examination revealed clusters of malignant cells. Electromyography and nerve conduction studies showed involvement of C-8 fibers proximal to the dorsal root ganglion.
The patient was started on Procarbazine, and re-evaluation in January, 1972 (after two courses of Procarbazine), indicated striking clinical and radiographic improvement. He was then free from interscapular cervicothoracic pain, and C-8 sensation had returned to normal. His hand grips were stronger, although hyperreflexia, ataxia, and gait disturbances were still present. Repeat Pantopaque myelography revealed disappearance of the block that had been present initially. Study of the cervical region showed widening of the cord suggestive of intramedullary seeding. Filling defects in the caudal subarachnoid space persisted.
Subsequently he has shown continuous clinical improvement. He has received eight courses of Procarbazine to date. Examination during his recent hospital admission (February, 1973) showed nystagmus in all directions of gaze. He had minimal right finger-nose ataxia. His sensory examination was within normal limits. Plantar reflexes were flexor. His gait was normal and he was able to run and play without difficulty. The CSF had a protein content of 145 mg% and contained no malignant cells.
Case 2. This 54-year-old right-handed man was admitted to the medical center on September 14, 1971, with a 3-month history of increasing headache, slowed mental reactions, confusion and right-sided weakness. At the time of admission he was taking Fro. 1. Case 1. Lumbar myelogram demonstrating multiple filling defects due to seeding from medulloblastoma.
Decadron (24 mg/day) prescribed by his referring neurosurgeon. Examination revealed marked dysphasia, bilateral papilledema with hemorrhages, right homonymous hemianopsia and right hemiparesis. A brain scan and angiogram confirmed a vascular left thalamic tumor. He was started on Procarbazine at 250 mg/day. He improved dramatically and Decadron was stopped at the beginning of the second course. Although examination of the optic discs revealed residual papilledema, his right F~. 2. Case 2. Serial brain scans showing decrease in tumor size. The patient was treated without operative confirmation and the provisional pre-chemotherapy diagnosis of glioblastoma multiforme was confirmed at autopsy. hemiparesis had disappeared and speech had returned to normal. Serial brain scans (Fig.  2) and a second angiogram confirmed striking regression of the tumor.
After an excellent remission lasting 7 months, he deteriorated and was hospitalized for the last time in April, 1972. His hospital course was one of rapid deterioration and he died on May 3. Autopsy confirmed a glioblastoma of the left thalamus.
We defined significant toxicity as a peripheral blood platelet count less than 30,000 cells/mm a or white blood cell (WBC) count less than 2000 cells/mm z. Leukopenia, thrombocytopenia, or both, developed in 75% of all patients. Leukopenia proved to be a more common problem The 14 patients evaluated received a total of 65 courses of Procarbazine (Table 4) . Nausea and vomiting, frequently noted during the first few days of most courses, was not a disqualifying side effect except in one case.
Complication
No. of Cases WBC count of 3000/ram ~ 14 platelet count of 30,000fmm 3 3 leukopenia/thrombocytopenia requiring hospitalization 8 rash 4 psychosis 3 than thrombocytopenia, the nadir for WBC ranging from 1500-4000 in most cases. While this was noted during the latter part of the 30-day period of drug administration, persistence for 4 to 6 weeks after cessation of drug was observed in several instances. Severe bone marrow depression requiring reverse isolation and other supportive measures occurred in eight patients (19%). Minor side effects included rash (4 cases) and psychosis (3 cases). Treatment was discontinued at the family's request because of persisting psychosis in one patient with a temporal lobe tumor (Case 12).
Discussion
Procarbazine can be added to the agents demonstrating activity against tumors involving the central nervous system. The unequivocal response rate of 41% noted in the present study approximates our previous experience with BCNU and CCNU. ~,9 Three of the four medulloblastomas have shown good responses, and one of these patients has enjoyed a remission for 19 months.
The majority of our patients (39 of 43) had had some form of previous therapy, and many were far advanced in their disease when Procarbazine therapy was initiated. This factor explains the relatively large number of patients who could not be evaluated and may account for the unresponsiveness of some patients with bulky tumors and severe disability at the outset. The tumors of patients who had received previous chemotherapy with either CCNU or BCNU showed no response to Procarbazine. Although the number of patients is small, this experience suggests either cross resistance or a poor response in patients with more advanced tumors.
Procarbazine has the advantage of oral administration. Although the majority of our patients were admitted for 1 to 3 days for a thorough evaluation at the beginning of each course, ambulatory patients could be handled on an outpatient basis.
Leukopenia due to bone marrow depression has been the most common serious complication. Seven of the eight patients in whom WBC counts fell below 2000/mm 3 were managed successfully with reverse isolation and other supportive measures. Leukopenia (300 WBC/mm ~) and septicemia was a contributing factor as a cause of death in one patient.
Four cases of pulmonary embolism have been observed in this series of patients. We have not investigated the effects of Procarbazine on blood coagulation factors.
Initiation of Procarbazine therapy earlier in the course of disease should yield a better overall response than we observed in the present study. Procarbazine may prove to be a useful drug in combination with other chemotherapeutic agents, and we have activated a multiple drug protocol incorporating Procarbazine.
